Phenotypic Test Identifies Antibiotic-Resistant Bacterial Infections
|
By LabMedica International staff writers Posted on 04 Dec 2018 |

Image: The BD Phoenix identification and susceptibility combo panels (Photo courtesy of Becton, Dickinson and Company).
Carbapenemase-producing organisms (CPO) are gram-negative bacteria that are resistant to the carbapenem class of antibiotics, which are commonly used for severe or high-risk bacterial infections. Mortality related to CPO infection is quite high around the world, with reported rates from 22% to 72%.
A CPO detect test, which offers results in less than 36 hours, is expected to replace time-consuming, manual detection that can take up to 96 hours for results. The CPO detection test will be offered as part of the BD Phoenix gram-negative panels, which already use susceptibility testing to expose bacteria from a specific patient's infection to a variety of potential treatments or candidates to gauge how they respond.
The BD Phoenix CPO detect test has gained US Food and Drug Administration clearance. The test may help hospitals contain the spread of antimicrobial resistance (AMR) by shortening the time it takes to detect CPOs, thereby enabling the earlier implementation of infection control procedures and the initiation of appropriate antibiotic therapies designed for treating these infections.
Kenneth Thomson, PhD, clinical professor of Pathology and Laboratory Medicine at the University of Louisville School of Medicine, said, “The BD Phoenix CPO detect test is a completely new type of phenotypic test, and its range of automation and diagnostic capabilities is unmatched by all other currently marketed tests. It represents a significant advance in meeting an important clinical need for rapid detection of CPOs.”
Steve Conly, vice president and general manager of Microbiology for BD Diagnostic Systems, said, “The BD Phoenix CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management. Along with the BD Phoenix M50 instrument, this automated first-to-market, phenotypic test to detect CPOs, using the BD Phoenix system, expands the BD portfolio of solutions for identification and antimicrobial susceptibility testing and is another example of the company's commitment to providing solutions that help addressing the global burden of antimicrobial resistance.”
Related Links:
University of Louisville School of Medicine
A CPO detect test, which offers results in less than 36 hours, is expected to replace time-consuming, manual detection that can take up to 96 hours for results. The CPO detection test will be offered as part of the BD Phoenix gram-negative panels, which already use susceptibility testing to expose bacteria from a specific patient's infection to a variety of potential treatments or candidates to gauge how they respond.
The BD Phoenix CPO detect test has gained US Food and Drug Administration clearance. The test may help hospitals contain the spread of antimicrobial resistance (AMR) by shortening the time it takes to detect CPOs, thereby enabling the earlier implementation of infection control procedures and the initiation of appropriate antibiotic therapies designed for treating these infections.
Kenneth Thomson, PhD, clinical professor of Pathology and Laboratory Medicine at the University of Louisville School of Medicine, said, “The BD Phoenix CPO detect test is a completely new type of phenotypic test, and its range of automation and diagnostic capabilities is unmatched by all other currently marketed tests. It represents a significant advance in meeting an important clinical need for rapid detection of CPOs.”
Steve Conly, vice president and general manager of Microbiology for BD Diagnostic Systems, said, “The BD Phoenix CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management. Along with the BD Phoenix M50 instrument, this automated first-to-market, phenotypic test to detect CPOs, using the BD Phoenix system, expands the BD portfolio of solutions for identification and antimicrobial susceptibility testing and is another example of the company's commitment to providing solutions that help addressing the global burden of antimicrobial resistance.”
Related Links:
University of Louisville School of Medicine
Latest Microbiology News
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
- New Diagnostic Method Confirms Sepsis Infections Earlier
- New Markers Could Predict Risk of Severe Chlamydia Infection
- Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
- CRISPR-Based Saliva Test Detects Tuberculosis Directly from Sputum
- Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People
- Saliva Test Detects Implant-Related Microbial Risks
Channels
Clinical Chemistry
view channel
Online Tool Detects Drug Exposure Directly from Patient Samples
Doctors often rely on patient interviews and medical records to determine what medications a person has taken, but this information is frequently incomplete. People may forget drugs they used, take over-the-counter... Read more
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read moreMolecular Diagnostics
view channel
Ultrasensitive Method Detects Low-Frequency Cancer Mutations
Liquid biopsy has emerged as a promising approach for cancer detection and treatment monitoring, although its clinical impact has been limited by the extremely low levels of tumor-derived DNA circulating in blood.... Read more
Blood Test Enables Non-Invasive Endometriosis Detection
Endometriosis is a chronic, complex, yet relatively common gynecological disorder, reportedly affecting 1 in 10 adult and adolescent women. Endometriosis causes tissue similar to the lining of the uterus... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read morePathology
view channel
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read more
Common Health Issues Can Influence New Blood Tests for Alzheimer’s Disease
Blood-based tests for Alzheimer’s disease are transforming diagnosis by offering a simpler alternative to spinal taps and brain imaging. However, many people evaluated at memory clinics also live with... Read more
Blood Test Formula Identifies Chronic Liver Disease Patients with Higher Cancer Risk
Chronic liver disease affects millions worldwide and can progress silently to hepatocellular carcinoma (HCC), one of the deadliest cancers globally. While surveillance guidelines exist for patients with... Read moreTechnology
view channel
Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that is notoriously difficult to diagnose in its early stages. Early symptoms often overlap with other neurological... Read more
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








